The immune system and response to HER2-targeted treatment in breast cancer

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular signalling. A growing body of preclinical and clinical evidence shows that the immune system contributes substantially to the therapeutic effects of trastuzumab and other monoclonal antibodies in vivo. Furthermore, findings indicate that immune-related markers can provide useful predictive information and that increased clinical activity might follow activation of the immune system. Development of immunomodulatory drugs with remarkable activity in many solid tumours defines a scenario in which the combination of immune modulation with trastuzumab, or other HER2-directed drugs, will result in augmented response and clinical outcome.

Original languageEnglish
JournalThe Lancet Oncology
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Immune System
Breast Neoplasms
Monoclonal Antibodies
Growth Factor Receptors
Therapeutic Uses
Therapeutics
Pharmaceutical Preparations
Neoplasms
Biomarkers
Survival
Trastuzumab

ASJC Scopus subject areas

  • Oncology

Cite this

The immune system and response to HER2-targeted treatment in breast cancer. / Bianchini, Giampaolo; Gianni, Luca.

In: The Lancet Oncology, Vol. 15, No. 2, 02.2014.

Research output: Contribution to journalArticle

@article{93f46d847cc04c8292e86a30eec7712a,
title = "The immune system and response to HER2-targeted treatment in breast cancer",
abstract = "The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular signalling. A growing body of preclinical and clinical evidence shows that the immune system contributes substantially to the therapeutic effects of trastuzumab and other monoclonal antibodies in vivo. Furthermore, findings indicate that immune-related markers can provide useful predictive information and that increased clinical activity might follow activation of the immune system. Development of immunomodulatory drugs with remarkable activity in many solid tumours defines a scenario in which the combination of immune modulation with trastuzumab, or other HER2-directed drugs, will result in augmented response and clinical outcome.",
author = "Giampaolo Bianchini and Luca Gianni",
year = "2014",
month = "2",
doi = "10.1016/S1470-2045(13)70477-7",
language = "English",
volume = "15",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "2",

}

TY - JOUR

T1 - The immune system and response to HER2-targeted treatment in breast cancer

AU - Bianchini, Giampaolo

AU - Gianni, Luca

PY - 2014/2

Y1 - 2014/2

N2 - The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular signalling. A growing body of preclinical and clinical evidence shows that the immune system contributes substantially to the therapeutic effects of trastuzumab and other monoclonal antibodies in vivo. Furthermore, findings indicate that immune-related markers can provide useful predictive information and that increased clinical activity might follow activation of the immune system. Development of immunomodulatory drugs with remarkable activity in many solid tumours defines a scenario in which the combination of immune modulation with trastuzumab, or other HER2-directed drugs, will result in augmented response and clinical outcome.

AB - The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular signalling. A growing body of preclinical and clinical evidence shows that the immune system contributes substantially to the therapeutic effects of trastuzumab and other monoclonal antibodies in vivo. Furthermore, findings indicate that immune-related markers can provide useful predictive information and that increased clinical activity might follow activation of the immune system. Development of immunomodulatory drugs with remarkable activity in many solid tumours defines a scenario in which the combination of immune modulation with trastuzumab, or other HER2-directed drugs, will result in augmented response and clinical outcome.

UR - http://www.scopus.com/inward/record.url?scp=84892959147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892959147&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(13)70477-7

DO - 10.1016/S1470-2045(13)70477-7

M3 - Article

VL - 15

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 2

ER -